Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

DEXCOM, INC.

(DXCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Dexcom : to Present at 38th Annual J.P. Morgan Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
01/06/2020 | 08:46am EST

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 38th annual J.P. Morgan Healthcare Conference on January 13, 2020.

The presentation, which will occur live at the Westin St. Francis Hotel in San Francisco, is scheduled to begin at approximately 8:00 AM PST and will be concurrently webcast.

The link to the webcast will be available on the Dexcom IR website at investors.dexcom.com by navigating to “Events and Presentations.”

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on DEXCOM, INC.
02/13DEXCOM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
02/13DEXCOM : 4Q Earnings Snapshot
AQ
02/13DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..
AQ
02/13DEXCOM : Reports Fourth Quarter and Fiscal Year 2019 Financial Results
BU
02/10DEXCOM, INC. : annual earnings release
01/21DEXCOM SCHEDULES FOURTH QUARTER AND : 30 p.m. Eastern Time
BU
01/13DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..
AQ
01/13DEXCOM : Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter an..
BU
01/06DEXCOM : to Present at 38th Annual J.P. Morgan Healthcare Conference
BU
2019ELI LILLY AND COMPANY : - Lilly to Integrate Dexcom CGM into Personalized Diabet..
AQ
More news
Financials (USD)
Sales 2020 1 782 M
EBIT 2020 238 M
Net income 2020 182 M
Finance 2020 37,7 M
Yield 2020 -
P/E ratio 2020 152x
P/E ratio 2021 103x
EV / Sales2020 14,6x
EV / Sales2021 11,8x
Capitalization 26 004 M
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 285,00  $
Last Close Price 283,91  $
Spread / Highest target 11,3%
Spread / Average Target 0,38%
Spread / Lowest Target -34,8%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Quentin S. Blackford Chief Operating & Financial Officer
Andrew K. Balo EVP-Clinical, Regulatory Affairs & Quality
Jacob Leach Chief Technology Officer
Jay S. Skyler Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.29.79%26 004
MEDTRONIC PLC3.42%157 266
BAXTER INTERNATIONAL INC.11.38%47 553
HOYA CORPORATION-0.73%34 919
ZIMMER BIOMET HOLDINGS7.16%32 992
TERUMO CORPORATION3.59%26 683